The CheckMate‐358 targeted both PD‐L1 and CTLA‐4, and demonstrated an ORR of 40% in patients with HPV‐positive/unknown cervical cancer using NIVO1 plus IPI3 regimen (i.e. 1 mg/kg nivolumab plus 3 mg/kg ipilimumab every 3 weeks for four cycles followed by 240 mg nivolumab every 2 weeks), in comparison to 26% with nivolumab alone.32, 33. This evidence concerns the gene CD274 and cervical cancer.